Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Citigroup Analyst Says

Biomea Fusion (NASDAQ:BMEA) had its price target raised by equities researchers at Citigroup from $6.00 to $7.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s target price indicates a potential upside of 430.30% from the stock’s previous close.

A number of other research firms have also issued reports on BMEA. Weiss Ratings reissued a “sell (e+)” rating on shares of Biomea Fusion in a research report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Biomea Fusion in a research note on Wednesday. Finally, Rodman & Renshaw began coverage on shares of Biomea Fusion in a research report on Tuesday, January 13th. They issued a “buy” rating and a $8.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Biomea Fusion Trading Down 3.6%

Shares of Biomea Fusion stock opened at $1.32 on Friday. Biomea Fusion has a 1 year low of $0.87 and a 1 year high of $3.08. The company has a market cap of $95.44 million, a P/E ratio of -1.01 and a beta of -0.20. The stock has a 50-day moving average price of $1.29 and a 200 day moving average price of $1.42.

Institutional Investors Weigh In On Biomea Fusion

Hedge funds and other institutional investors have recently made changes to their positions in the company. Aisling Capital Management LP grew its stake in shares of Biomea Fusion by 156.5% in the 2nd quarter. Aisling Capital Management LP now owns 2,048,757 shares of the company’s stock valued at $3,688,000 after buying an additional 1,250,000 shares in the last quarter. Barclays PLC increased its holdings in Biomea Fusion by 1,731.0% in the fourth quarter. Barclays PLC now owns 59,013 shares of the company’s stock worth $73,000 after buying an additional 55,790 shares during the last quarter. Jain Global LLC bought a new position in Biomea Fusion during the fourth quarter valued at approximately $68,000. ADAR1 Capital Management LLC bought a new position in Biomea Fusion during the fourth quarter valued at approximately $54,000. Finally, Virtu Financial LLC acquired a new stake in Biomea Fusion in the third quarter valued at approximately $39,000. 96.72% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Citigroup raised its price target on BMEA from $6.00 to $7.00 and reiterated a “buy” rating — the new target implies substantial upside versus the current share level. Read More.
• Positive Sentiment: HC Wainwright published a set of updated EPS forecasts (Q1–Q4 2026 and FY2026–FY2028) and materially lifted its multi-year loss estimates (FY2026 from ($1.37) to ($0.57); FY2027 to ($0.64); FY2028 to ($0.78)), signaling the firm expects smaller losses and improving financials over time. The report also lists per-quarter EPS expectations for 2026. Read More.
• Positive Sentiment: D. Boral Capital initiated/maintained a buy rating on Biomea Fusion, adding another independent positive analyst voice. Read More.
• Positive Sentiment: Recent coverage highlights continued strong analyst sentiment driven by encouraging diabetes trial results, supporting the investment case for BMEA’s pipeline upside. Read More.
• Neutral Sentiment: Despite the positive analyst action and trial commentary, the stock is trading lower today — likely a short-term reaction (profit-taking, low liquidity, or risk-off flows common in small-cap biotech) rather than a reversal of analyst views. Monitor trading volume and upcoming clinical or corporate catalysts for signs of follow-through.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.